All criteria in accordance with the Summary of Product Characteristics of Bondronat (ibandronate)

Adult patients greater than (\>) 18 years of age

Histologically confirmed breast cancer

Confirmed bone metastasis (by bone scintigraphy, X-ray, computed tomography or magnetic resonance imaging)

Life expectancy \>6 months

No previous bisphosphonate therapy

Patients signed written informed consent form before study start

An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)